Condition (MeSH)
Unilateral Breast Neoplasms
ClinicalTrials.gov lists 16 trials for Unilateral Breast Neoplasms or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
16 of the 16 trials are tagged with Unilateral Breast Neoplasms itself; the rest are tagged with a narrower condition beneath it.
When did Unilateral Breast Neoplasms trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 2 |
| 2016 | 1 |
| 2014 | 1 |
| 2011 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Unilateral Breast Neoplasms trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 2 |
| Not applicable | 7 |
| Observational | 3 |
How many Unilateral Breast Neoplasms trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Active, not recruiting | 2 |
| Completed | 6 |
| Terminated | 1 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Unilateral Breast Neoplasms trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pfizer | 2 |
| Central Hospital Saint Quentin | 1 |
Which drugs are being tested for Unilateral Breast Neoplasms? (8)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Abemaciclib | 2 |
| FULVESTRANT | 1 |
| Cytoxan | 1 |
| EVEROLIMUS | 1 |
| PF-07248144 | 1 |
Showing 5 of 8 drugs.
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Letrozol (Femara, Novartis) | 1 |
| Palbociclib Pill | 1 |
| Sagramostim | 1 |
| Niraparib Pill | 1 |
| Multi-epitope Folate Receptor Alpha Peptide Vaccine | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Unilateral Breast Neoplasms trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Injection site reaction | 8 | 1 |
| Fatigue | 6 | 1 |
| Peripheral sensory neuropathy | 5 | 1 |
| Lung infection | 3 | 1 |
| Neutrophil count decreased | 3 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Unilateral Breast Neoplasms? (19)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Oncoplastic Entirely Robot-Assisted Approach: Incorporating Robotic Surgery in Both Mastectomy and DIEP Flap Reconstruction. | Plastic and reconstructive surgery | 2025 | Yes |
| The effect of different nerve block strategies on the quality of post-operative recovery in breast cancer patients: A randomized controlled study. | European journal of pain (London, England) | 2024 | Yes |
| BRAVEHeart: a randomised trial comparing the accuracy of Breathe Well and RPM for deep inspiration breath hold breast cancer radiotherapy. | Trials | 2023 | Yes |
| Emotion regulation and choice of bilateral mastectomy for the treatment of unilateral breast cancer. | Cancer medicine | 2023 | Yes |
| Reproducibility of repeated breathhold and impact of breathhold failure in whole breast and regional nodal irradiation in prone crawl position. | Scientific reports | 2022 | Yes |
Showing 5 of 19 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.